| Literature DB >> 23463461 |
Abstract
In recent years it could be shown that systemic inflammation, which typically occurs in chronic inflammatory rheumatic diseases, significantly contributes to cardiovascular morbidity and mortality. All rheumatic diseases inherit this enhanced risk for cardiovascular complications with rheumatoid arthritis being one of the most prominent. As the underlying pathophysiological mechanisms are very similar with respect to endothelial damage all rheumatic diseases and specifically rheumatoid arthritis should be monitored and treated with disease-modifying drugs and biological agents as consistently as possible to be able to improve the long-term outcome of affected patients as much as possible.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23463461 DOI: 10.1007/s00108-012-3188-1
Source DB: PubMed Journal: Internist (Berl) ISSN: 0020-9554 Impact factor: 0.743